GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Ringpu Bio-Technology Co Ltd (SZSE:300119) » Definitions » Piotroski F-Score

Tianjin Ringpu Bio-Technology Co (SZSE:300119) Piotroski F-Score : 7 (As of May. 22, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Tianjin Ringpu Bio-Technology Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Tianjin Ringpu Bio-Technology Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Tianjin Ringpu Bio-Technology Co's Piotroski F-Score or its related term are showing as below:

SZSE:300119' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Tianjin Ringpu Bio-Technology Co was 8. The lowest was 3. And the median was 6.


Tianjin Ringpu Bio-Technology Co Piotroski F-Score Historical Data

The historical data trend for Tianjin Ringpu Bio-Technology Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Ringpu Bio-Technology Co Piotroski F-Score Chart

Tianjin Ringpu Bio-Technology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 6.00 4.00 3.00 7.00

Tianjin Ringpu Bio-Technology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 5.00 5.00 7.00 7.00

Competitive Comparison of Tianjin Ringpu Bio-Technology Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Ringpu Bio-Technology Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Ringpu Bio-Technology Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Ringpu Bio-Technology Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Tianjin Ringpu Bio-Technology Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 97.448 + 95.427 + 179.244 + 87.571 = ¥460 Mil.
Cash Flow from Operations was 107.547 + 60.208 + 181.229 + 89.136 = ¥438 Mil.
Revenue was 551.316 + 593.069 + 661.797 + 533.199 = ¥2,339 Mil.
Gross Profit was 291.007 + 291.912 + 308.824 + 254.471 = ¥1,146 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(6029.892 + 6112.588 + 6218.503 + 6595.942 + 6664.48) / 5 = ¥6324.281 Mil.
Total Assets at the begining of this year (Mar23) was ¥6,030 Mil.
Long-Term Debt & Capital Lease Obligation was ¥411 Mil.
Total Current Assets was ¥3,379 Mil.
Total Current Liabilities was ¥1,231 Mil.
Net Income was 67.627 + 93.188 + 113.678 + 80.823 = ¥355 Mil.

Revenue was 517.531 + 568.424 + 607.489 + 442.78 = ¥2,136 Mil.
Gross Profit was 246.543 + 265.005 + 305.032 + 225.708 = ¥1,042 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(5618.732 + 5881.568 + 6178.266 + 6106.274 + 6029.892) / 5 = ¥5962.9464 Mil.
Total Assets at the begining of last year (Mar22) was ¥5,619 Mil.
Long-Term Debt & Capital Lease Obligation was ¥189 Mil.
Total Current Assets was ¥2,983 Mil.
Total Current Liabilities was ¥1,148 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Tianjin Ringpu Bio-Technology Co's current Net Income (TTM) was 460. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Tianjin Ringpu Bio-Technology Co's current Cash Flow from Operations (TTM) was 438. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=459.69/6029.892
=0.0762352

ROA (Last Year)=Net Income/Total Assets (Mar22)
=355.316/5618.732
=0.06323776

Tianjin Ringpu Bio-Technology Co's return on assets of this year was 0.0762352. Tianjin Ringpu Bio-Technology Co's return on assets of last year was 0.06323776. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Tianjin Ringpu Bio-Technology Co's current Net Income (TTM) was 460. Tianjin Ringpu Bio-Technology Co's current Cash Flow from Operations (TTM) was 438. ==> 438 <= 460 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=410.754/6324.281
=0.06494873

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=188.724/5962.9464
=0.03164945

Tianjin Ringpu Bio-Technology Co's gearing of this year was 0.06494873. Tianjin Ringpu Bio-Technology Co's gearing of last year was 0.03164945. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=3378.521/1230.805
=2.74496854

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=2983.123/1147.847
=2.59888557

Tianjin Ringpu Bio-Technology Co's current ratio of this year was 2.74496854. Tianjin Ringpu Bio-Technology Co's current ratio of last year was 2.59888557. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Tianjin Ringpu Bio-Technology Co's number of shares in issue this year was 460.658. Tianjin Ringpu Bio-Technology Co's number of shares in issue last year was 463.969. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1146.214/2339.381
=0.48996465

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1042.288/2136.224
=0.48791138

Tianjin Ringpu Bio-Technology Co's gross margin of this year was 0.48996465. Tianjin Ringpu Bio-Technology Co's gross margin of last year was 0.48791138. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=2339.381/6029.892
=0.387964

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=2136.224/5618.732
=0.38019681

Tianjin Ringpu Bio-Technology Co's asset turnover of this year was 0.387964. Tianjin Ringpu Bio-Technology Co's asset turnover of last year was 0.38019681. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+0+1+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Tianjin Ringpu Bio-Technology Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Tianjin Ringpu Bio-Technology Co  (SZSE:300119) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Tianjin Ringpu Bio-Technology Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Tianjin Ringpu Bio-Technology Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Ringpu Bio-Technology Co (SZSE:300119) Business Description

Traded in Other Exchanges
N/A
Address
No.6, Liujing Road, Developing Zone, Tianjin, CHN, 300300
Tianjin Ringpu Bio-Technology Co Ltd is a China-based company. It is engaged in biotechnology and animal medicine, focusing on the national demand for agricultural sustainable development. The company provides products for Poultry; Swine; Pet; Aquatic; and Cattle and Sheep.

Tianjin Ringpu Bio-Technology Co (SZSE:300119) Headlines

No Headlines